ArticleFrontiers in immunology2026
LY-H as a potential screening biomarker for lymphocyte activation in peripheral blood.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Viral infections often cause morphological changes in peripheral blood lymphocytes. While the presence of reactive lymphocytes in blood smears reflects lymphocyte activation, their identification is often affected by morphological heterogeneity and observer subjectivity. This study evaluates the correlation between LY-H, defined as the vector sum of lymphocyte parameters LY-Y and LY-Z, and the presence of reactive lymphocytes in peripheral blood smears, exploring its potential as a screening marker for lymphocyte activation. Methods: Data from 404 individuals were collected and divided into four groups: 109 individuals with reactive lymphocytes found in peripheral blood smears (reactive lymphocyte group), 104 lymphoma patients (lymphoma group), 91 patients with acute lymphocytic leukemia (ALL group), and 100 patients with chronic lymphocytic leukemia (CLL group). Differences in LY-H among the four groups were compared. Logistic regression and smooth spline analysis were used to analyze the predictive value and correlation of lymphocyte parameters with reactive lymphocyte proportion. Receiver operating characteristic (ROC) curves were generated to evaluate the predictive value of LY-H for reactive lymphocytes detected by microscopy. Results: LY-H levels were significantly higher in the reactive lymphocyte group than in the other three groups ( Conclusions: Novel parameter LY-H correlates closely with the reactive lymphocytes identified in peripheral blood smears. It serves as a potential indicator for assessing lymphocyte activation status in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.